Biognosys raises €59.9M Growth round
4 January 2023· Schlieren, Switzerland· biotech, proteomics, mass_spectrometry, industrial_software, b2b, software_hardware
Bruker made a majority-ownership investment in Biognosys to form a strategic partnership aimed at expanding Biognosys' CRO business, making advanced proteomics research services, software, and kits globally accessible to Biopharma and Biomarker Customers, and opening an advanced US proteomics CRO facility for biomarker and drug discovery and development.
Investors
LeadBruker Corporation
About Biognosys
Stage
Growth
Headquarters
Schlieren, Switzerland
Founded
2008
Team Size
51–200
Sectors
biotechproteomicsmass_spectrometryindustrial_softwareb2bsoftware_hardware